SciNeuro Pharmaceuticals has secured a $53 million private investment to advance its lead candidate, a brain-penetrant LRRK2 inhibitor for Parkinson's disease, into a Phase 2 trial. The Shanghai- and Boston-based biotech is developing small molecules for neurodegenerative disorders, with its lead program, SN002, designed to inhibit the leucine-rich repeat kinase 2 (LRRK2), a genetically validated target in Parkinson's. The new capital is earmarked specifically to initiate and enroll patients in a Phase 2 clinical study for SN002, with remaining funds supporting pipeline expansion. While the investor syndicate was not disclosed, the PIPE structure suggests backing from specialized institutional investors familiar with high-risk, high-reward neuroscience assets. The deal highlights continued, though selective, investor appetite for novel mechanisms in neurodegenerative diseases, where successful clinical data can command significant premiums.